We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Nimbus Organized Annual ADME Meeting

Nimbus Organized Annual ADME Meeting

Nimbus Organized Annual ADME Meeting

Nimbus Organized Annual ADME Meeting

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Nimbus Organized Annual ADME Meeting"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

"Discover the hidden properties!" was the slogan of the annual ADME meeting organized by Nimbus Biotechnology.

During this outstanding meeting scientists presented and discussed current strategies for ADME issues.

Dr. Keldenich (Bayer HealthCare AG, Germany) reported in his presentation about a correlation of membrane affinity measured by the well known TRANSIL® technology to the permeability determinate by double sink PAMPA for a subset of compounds. 

He also pointed out that the TRANSIL® technology has additionally advantages like reliability and easiness of the assays for membrane affinity.

In this respect Dr. Schmitt (Bayer Technology Services, Germany) said in his presentation that the membrane affinity hide much additional information about a compound.

To discover those properties it is necessary to use this physicochemical data as an input parameter of physiology based pharmacokinetic modelling, so that the user is able to predict important ADME parameters like fraction absorbed, fraction unbound, volume of distribution or plasma/organ partitioning coefficients. 

Wolfgang Lerch, CEO of NIMBUS Biotechnology, stated that, "The membrane affinity is a reliable, fast and easy to measure parameter which hide important information like a gold mine."

"During the meeting it was impressively demonstrated by several speakers that TRANSIL® ADME assays are extremely valuable for drug discovery."